Does Orforglipron Interact with Simvastatin?
CDI records a major classification for Orforglipron and Simvastatin. The stored summary is: Do not exceed simvastatin 20 mg once daily; concomitant use increases simvastatin acid exposure two-fold, which may be clinically meaningful. The mechanism involves foundayo increases exposure of active metabolite simvastatin acid. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This record was extracted from drug labeling through openFDA. NIH/NLM RxNorm is used for drug identities. The summary and severity classification are CDI's processed information, not a verbatim source quotation. Product, route, and patient circumstances matter.
- Severity
- Major
- Simvastatin Class
- HMG-CoA Reductase Inhibitor
- Management
- Close medical supervision required
- Data Source
- U.S. FDA via OpenFDA
Recorded Mechanism
FOUNDAYO increases exposure of active metabolite simvastatin acid
What To Tell Your Doctor or Pharmacist
If you are taking Orforglipron and your doctor is considering prescribing Simvastatin (or vice versa), make sure to:
- Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
- Ask whether the benefits of combining these medications outweigh the risks for your specific situation
- Ask what symptoms to watch for that would indicate the interaction is causing problems
- Ask how frequently you should be monitored while these are co-prescribed
- Ask whether any dosage adjustments are needed
- Never stop or change either medication without first consulting your healthcare provider